Trillium Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics

TRIL 20.36

+2.0%

2:56 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	1/12/2018 2:40:42 PM
	of 294

Mr. James Parsons Chief Financial Officer Mr. Parsons is responsible for financial and risk management, investor relations, corporate governance and administration. He has an extensive background in the life sciences industry and over 25 years of financial management experience. His past involvement in biotechnology includes roles with Amorfix Life Sciences Ltd, DiaMedica Inc, Trillium Therapeutics Inc and YM BioSciences Inc. Mr. Parsons serves on the board of Sernova Corp where he chairs the audit committee. He has a Master of Accounting degree from the University of Waterloo and is a Chartered Professional Accountant and Chartered Accountant. trilliumtherapeutics.com ***************************** Past involvement in Trillium Therapeutics? They're busy revising the header for this thread, and they have their CFO listed as having PAST experience with Trillium? This is how Amorfix raised cash, 2015...... newswire.ca Currently trades at a MC of 50 million, with 220 million shares outstanding. DiaMedica trades at a MC of 38 million, with 127 million shares out. Sernova trades at a MC of $68m, with 159 million shares out.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next